Welcome to our dedicated page for BIOMARK DIAGNOSTICS news (Ticker: $BMKDF), a resource for investors and traders seeking the latest updates and insights on BIOMARK DIAGNOSTICS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BIOMARK DIAGNOSTICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BIOMARK DIAGNOSTICS's position in the market.
Rhea-AI Summary
BioMark Diagnostics Inc. announces the extension of 5,062,000 non-broker warrants with an exercise price of C$0.45 until May 4th, 2026. The company also grants 4,625,000 stock options to key personnel at a purchase price of $0.45 per share, vesting over a three-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
-
Rhea-AI Summary
BioMark Diagnostics Inc. secures research funding for a cancer treatment study for Glioblastoma. The project aims to develop a drug delivery platform for improved radiation responses in various cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
-
News
Rhea-AI Summary
BioMark Diagnostics Inc. and Rubix LS announce a strategic partnership to develop better diagnostic tools for lung and breast cancer screening, focusing on underserved communities. The collaboration aims to enhance early detection and personalized treatment for hard-to-detect cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
BioMark Diagnostics Inc. announces the addition of Theresa Peterson to its Advisory team. Peterson's expertise in funding opportunities and relationship-building is expected to enhance BioMark's growth and expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) has closed a financing round, raising $1,900,000 for the commercialization of its liquid biopsy technology. The financing included a non-brokered private placement and a debt conversion. The company also received non-dilutive funding of CAD $231,000 from the City of Quebec. BioMark plans to introduce its early lung cancer diagnostics assay within the next 6-9 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) has been granted patent N° 2.906.236 by the Canadian Intellectual Property Office for their legacy assay 'Detection and Quantification of Acetylamantadine in Urine Sample.' The patent strengthens their metabolite measurement capabilities, expanding options to quantify the substrate of interest using Raman spectroscopy. The company is conducting clinical studies for measuring response to treatment for glioblastoma and advanced-stage lung cancer, with results expected in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
News
Rhea-AI Summary
BioMark Diagnostics Inc. (BUX) reports strong operational results for the second quarter, with expanded technical team, new hires, and funding support for the launch of its early lung cancer assay in 2024. The company also announces an extension of the warrant exercise term to improve corporate value for its shareholders. The unaudited consolidated results show revenues of CA$81,872 for the six months ended September 30, 2023, and a 15% increase in Research & Development expenses compared to the same period last year. Cash, short-term, and long-term investments stood at C$632,238 as of September 30, 2023. The number of outstanding common shares was 83,286,229, with 12,534,579 stock options and warrants issued. The company intends to extend the term of non-broker warrants issued in relation to a private placement financing that closed on December 13, 2019, to December 13, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) announces the appointment of Dr. W. Randolph Ford to its Advisory team to enhance its data analytics and AI capabilities. Dr. Ford's expertise will support the commercial acceleration of BioMark's early cancer detection technology, with a focus on hard-to-detect and treat cancers. The company has seen a boost in its diagnostic assay performance by incorporating AI and sophisticated data analytic techniques provided by Dr. Ford. Exciting early breast detection data analysis will be presented at the upcoming San Antonio Breast Cancer Symposium. Dr. Ford's experience and connections will be invaluable as BioMark evolves into a commercial entity with strong AI and ML embedded capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.4%
Tags
-
Rhea-AI Summary
BioMark Diagnostics Inc. has been awarded non-dilutive funding of CAD $231,000 from the City of Quebec to accelerate commercialization and market development activities of its proprietary assay for early detection of lung cancer. The company plans to use the funding to support business development and commercialization of its liquid biopsy assay for early cancer detection and treatment management, leveraging its Quebec-based fully equipped laboratory.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
Rhea-AI Summary
BioMark Diagnostics announces acceptance of abstract for poster presentation at San Antonio Breast Cancer Symposium
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
BIOMARK DIAGNOSTICS INC
OTC:BMKDF
BMKDF Rankings
BMKDF Stock Data
18.46M
39.24M
50.22%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
Richmond